Heart failure & cardiomyopathiesRandomised controlled trial
Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use
- Design paper of a cluster-randomised pragmatic trial
- controlled
Study context
- Population
- Outpatients with heart failure with reduced ejection fraction (HFrEF) and their outpatient providers119 providers randomised
- Participants
- 1,210 outpatients
- Comparison
- Tailored best practice alert (BPA) vs usual care
- Primary endpoint
- MRA prescriptions
- Follow-up
- 6 months following randomization
Primary result
As reported in the abstract
- Design paper: enrollment completed; no outcome results reported
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC Heart Fail. Published 8 November 2023. doi:10.1016/j.jchf.2023.08.025
Summarised from the published abstract; every number is checked against it